

ORAL PRESENTATION

Open Access

Ongoing validation of health-related quality of life instruments

Kim Cocks*, Puvan Tharmanathan

From 3rd International Clinical Trials Methodology Conference Glasgow, UK. 16-17 November 2015

Background

Validated health-related quality of life (HRQOL) instruments may require updating as they begin to be used in randomised controlled trials (RCTs) containing patient populations and novel drugs that did not form part of the original validation study. Multiple myeloma (MM) is one example where new classes of drugs are rapidly emerging. There are a number of commonly used HRQOL instruments used, some generic and some MM specific but it is unclear how valid existing instruments will be in RCTs of novel agents. We aim to make recommendations for ongoing validation of HRQOL instruments in RCTs applicable to many disease areas using empirical evidence from the case of MM.

Methods

We searched MEDLINE for RCT's in MM measuring HRQOL conducted in the last 10 years. We also surveyed instrument publications and websites in order to determine whether the instrument was validated for use in the RCT population, how long ago and whether there are provisions for ongoing validation.

Results

Our search returned 146 abstracts. Validation studies sometimes contained a small sample of sub-populations of a disease (e.g. the EORTC QLQ-MY20 validation sample had 225 newly diagnosed and only 15 relapsed patients).

Conclusions

Health-related quality of life instruments should be subjected to ongoing validation to ensure they remain relevant in their field and for specific clinical trial patient populations. We discuss simple psychometrics that can be incorporated into the RCT statistical analysis plan and

adding debrief questions to the instrument could provide additional insight, particularly in phase II studies of novel drugs.

Published: 16 November 2015

doi:10.1186/1745-6215-16-S2-O8

Cite this article as: Cocks and Tharmanathan: Ongoing validation of health-related quality of life instruments. *Trials* 2015 16(Suppl 2):O8.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



York Trials Unit, University of York, York, UK

